Products with Sedative hypnotics bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1904 | Convolvine |
| 1. Convolvine and its derivatives exhibit pronounced antihypoxic, immunomodulating, and anti-inflammatory activity. 2. Convolvine blocks the M-receptors of the heart and intestine but raises the sensitivity of the M-receptors of the salivary gland and of the CNS,convolvine has revealed characteristics of a sedative and nootropic agent. 3. Convolvine and its derivatives exhibit cytotoxic activity, the alkaloids N-benzylconvolvine and N-chloroacetylconvolvine at concentrations of 10 ug/mL exhibit the greatest activity against HeLa and Hep cancer cell cultures. | |
| BCN2160 | Sodium barbital |
| 1. Sodium barbital was used as a model non-genotoxic renal carcinogen to test whether a concentration that increased renal tubular proliferation without severe nephrotoxicity would enhance tumor induction in a hereditary tumor model. 2. Sodium barbital causes progression to the stage of spontaneous renal lesions in Tsc2 mutant rats but do not increase their overall number. 3. Sodium barbital is a depressant of the central nervous system, has sedative/hypnotic effects. 4. Sodium barbital as an inhibitor of rabbit-muscle creatine kinase (CK), it might compete with both creatine and ATP, but mainly with creatine, to inhibit the activity of CK. 5. Sodium barbital is a tumour promoter, it can shorten the otherwise long latency between exposure to toxin and tumourigenesis. | |
| BCN2175 | Pregabalin |
| Pregabalin, a potent anticonvulsant agent, is used in treatment-resistant epileptic patients.Pregabalin (30 and 100mg/kg) presents central spinal but not central supraspinal antinociceptive effect and Pregabalin 100mg/kg shows peripheral antinociceptive effect. Pregabalin may be effective for the reduction of neuropathic pain, it improves postoperative analgesia compared with placebo at the expense of increased sedation and visual disturbances. | |
| BCN2183 | Ramelteon |
| 1. Ramelteon significantly improves symptoms in patients with gastroesophageal reflux disease and significantly improves patients' sleep experience. 2. Ramelteon could be a potential therapeutic drug, in adjunctive treatment of learning and memory deficits seen in patients with schizophrenia. 3. Ramelteon is effective for the prevention of delirium, ramelteon administered nightly to elderly patients admitted for acute care may provide protection against delirium. 4. Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for insomnia treatment, demonstrates no significant effects indicative of potential for abuse or motor and cognitive impairment at up to 20 times the recommended therapeutic dose. | |
| BCN2371 | Trigonelline |
| Trigonelline (1-methylpyridinium-3-carboxylate), an alkaloid present in coffee and fenugreek seed, exhibits phytoestrogenic, anti-adipogenesis, and anticancer activities, it also can reduce early glucose and insulin responses. Trigonelline has inhibition of the Nrf2 transcription factor and PPAR-γ. | |
